Establish the cause and threat to vision first. Control inflammation promptly, then choose a sustainable treatment that protects vision while limiting corticosteroid and immunosuppressive harm.
Terminology and draft status
Original terms and source questions are retained. Four WHO UMD entries were inspected; further Arabic medical terms remain working translations pending terminology and medical review. Source, translation and medical approval remain pending.
01Start with the diagnosis and treatment goal
Uveitis may be infectious, noninfectious or a masquerade syndrome, such as an infiltrative or neoplastic disorder. Noninfectious does not automatically mean a proven autoimmune cause. Reassess relevant infection and malignancy before increasing immune suppression, particularly when the course is atypical. 1 6
The Step-Ladder framework moves from rapid corticosteroid control towards sustainable steroid-sparing immunomodulatory therapy (IMT). Local treatment and systemic treatment are different tools; nonsteroidal anti-inflammatory drugs (NSAIDs) are adjuncts in selected situations, not an obligatory intermediate stage. 1 6
Sympathetic ophthalmia (SO), Vogt–Koyanagi–Harada (VKH) disease, serpiginous choroiditis, severe systemic lupus and posterior Behçet disease need prompt disease-specific assessment. These names do not establish one universal “highest step”; an infectious serpiginous-like presentation requires a different approach. The current EULAR Behçet update supports early monoclonal TNF inhibition for organ- or life-threatening disease, within multidisciplinary care. 1 14
Escalation is considered for sight-threatening inflammation, inadequate steroid response, recurrence during taper, unacceptable toxicity or persistent steroid dependence. The original examples of relapse below 20 mg/day and dependence above 7.5 mg/day prednisone are clinical prompts, not automatic thresholds independent of the diagnosis. Agree goals, safety monitoring and reproductive plans with the patient. 1 6
02Use corticosteroids by the route the disease requires
Corticosteroids rapidly suppress inflammation. “Hit hard” means achieve adequate early control, then taper under supervision towards the lowest effective exposure and, where feasible, withdrawal. It does not justify an unsupervised high dose, abrupt stopping or the same schedule for every patient. 1
Prednisolone acetate 1% (Pred Forte) and difluprednate 0.05% are original topical examples for anterior activity. Drops alone usually do not provide adequate treatment of posterior inflammation, but associated substantial anterior inflammation in intermediate uveitis may still warrant drops. 1 10
A randomised short-term study in mild-to-moderate endogenous anterior uveitis compared difluprednate four times daily in 56 patients with prednisolone acetate eight times daily in 54. After 14 days, mean anterior-chamber cell-grade changes were −2.2 versus −2.0 (P=.16); the authors reported noninferiority. Treatment was followed by 14 days of taper and 14 days of observation. This does not establish universal dose equivalence or long-term comparative cataract safety. 10
At day 3 in that trial, mean intraocular pressure (IOP) rose 2.5 versus 0.1 mmHg (P=.0013). Group mean IOP below 21 mmHg during follow-up does not exclude individual pressure spikes. Monitor pressure and lens effects with either steroid; a short study cannot establish a general glaucoma-risk ranking. 10
Periocular routes include posterior sub-Tenon injection, often superotemporal to place a depot near the posterior globe, transseptal delivery towards the orbital floor, and subconjunctival injection for anterior disease. The original names Depo-Medrol, triamcinolone, Decadron and betamethasone are retained: molecule, formulation, authorised route and procedural risk must be checked separately; these products are not interchangeable injection instructions. 1
Intravitreal triamcinolone is an off-label option in relevant settings. The EMA Ozurdex dexamethasone implant indication includes adult noninfectious posterior-segment inflammation; the UK Iluvien fluocinolone label covers relapse prevention in recurrent noninfectious posterior disease. Original durations of 3–6 months and 1–3 years are approximate teaching descriptions, not guaranteed disease control: Iluvien releases drug for up to 36 months, and Ozurdex retreatment depends on response and benefit–risk. 9 13
Intravitreal treatment carries infection, cataract, IOP, retinal-detachment and implant-migration risks. Check each implant’s infection, glaucoma, capsule and lens restrictions and arrange product-specific follow-up. A local depot does not remove the need to consider systemic disease or alternative causes of inflammation. 9 13
Systemic treatment may use oral or intravenous corticosteroids, but oral prednisone is not the name of every intravenous preparation. Match the actual molecule and formulation. Cataract, glaucoma, diabetes, hypertension, cardiovascular, bone and psychiatric harm depend on exposure and susceptibility; 7.5 mg/day is not a no-risk boundary. Allergy, active fungal infection, major cardiac or psychiatric disease and gastrointestinal bleeding require formulation-specific contraindication and risk assessment, not one undifferentiated list. 1 7
03Give NSAIDs a defined adjunctive role
Topical NSAIDs, for example ketorolac, are discussed for adjunctive anterior inflammation and cystoid macular oedema (CME), especially after cataract surgery in a pseudophakic eye with an intraocular lens (IOL). Pseudophakic CME and inflammatory uveitic CME are not interchangeable study populations; these drops are not a substitute for adequate posterior uveitis treatment. 1
The original discussion also names giant-cell deposits on an IOL and steroid reduction. The claimed high efficacy and safety over months remain unverified for that specific setting. Evaluate ocular-surface and corneal risk, the cause of the deposits and the continuing need for treatment rather than promising universal long-term safety. 1
Oral NSAIDs, for example ibuprofen, have a selected role in scleritis and some anterior inflammatory settings; scleritis is a distinct diagnosis. Look for systemic vasculitis and disease severity rather than using a negative screen as sufficient permission. Gastrointestinal bleeding, renal and cardiovascular harm and hypertension require individual review. The original 6-month blood-count, liver-test and blood-pressure schedule is not a universal current monitoring protocol. 1
04Choose an antimetabolite for sustained control
Methotrexate (MTX), azathioprine (AZA) and mycophenolate mofetil (MMF) inhibit pathways needed for immune-cell function. Their onset is slower than immediate steroid control, so bridging and follow-up matter. Historical response percentages in the table are retained for traceability; different cohorts, endpoints and observation periods cannot establish comparative superiority. 1 3 6
FAST randomised 216 patients aged at least 16 years with active noninfectious intermediate, posterior or panuveitis to oral MTX 25 mg weekly or MMF 3 g daily after a tolerability phase. Among 194 evaluable at six months, composite success was 64/96 (66.7%) versus 56/98 (57.1%): difference 9.5 percentage points, 95% confidence interval −5.3 to 21.8; odds ratio 1.50 (0.81–2.81), P=.20. Success required inflammatory control with prednisone ≤7.5 mg/day, ≤2 daily prednisolone 1% drops and no safety or tolerance failure. 3
FAST did not show MMF superiority. Its prespecified secondary noninferiority analysis used a 10-percentage-point margin; the lower confidence bound −5.3 supported MTX noninferiority within that design. Outcome graders were masked, patients were not; 22 participants lacked six-month follow-up. Subgroup interaction P=.004 is exploratory in the setting of multiple secondary comparisons, not a diagnosis-specific prescribing rule. Liver-enzyme elevations were reported in 14 (13.0%) versus 8 (7.4%). 3
MTX must be taken once weekly, not daily; a daily dosing error can be fatal. Plan folate supplementation, blood-count, liver and renal monitoring and interaction checks. The inspected Nordimet and CellCept labels contraindicate MTX and MMF during breastfeeding and restrict their use in pregnancy; MMF is strongly teratogenic. In contrast, EULAR reproductive guidance considers AZA, ciclosporin and tacrolimus compatible in selected pregnancy and lactation settings. Compatibility requires specialist planning and the actual local label; it does not mean risk-free use. 7 8 11
| Drug | Original administration claim | Original response/onset claim | Clinical interpretation and safety |
|---|---|---|---|
| Methotrexate (MTX) | Once weekly; original start 5–7.5 mg, maximum 25 mg; oral, SC, IM or IV. | 6–8 weeks, full effect at 6 months; up to 66%. | Historical figures, not a universal prescription. Original nausea ~25% and liver inflammation ~15% need source denominators. Folate, marrow/liver/renal checks; pregnancy and breastfeeding contraindications in inspected label. Routes are not dose-interchangeable. |
| Azathioprine (AZA) | Original adult 100–150 mg daily; individual regimen required. | 6 weeks–6 months; ~62%, intermediate disease 90%; intolerance 24%. | Unverified cohort figures; no universal ranking. Marrow/liver risk and interaction assessment; original “safe in pregnancy” becomes conditional specialist compatibility, not zero risk. |
| Mycophenolate mofetil (MMF) | Original empty-stomach rule: 1 hour before / 2 hours after food; check actual formulation. | Original onset similar to AZA; up to 73%; intolerance 12%. | These figures do not establish better tolerability head to head. Pregnancy prevention, teratogenicity and breastfeeding restrictions; marrow/infection monitoring. |
05Assess renal and vascular risk with calcineurin inhibitors
Ciclosporin and tacrolimus inhibit calcineurin-dependent T-cell activation. They may be considered as alternatives or in selected combinations, such as MTX with ciclosporin, after considering diagnosis and accumulated toxicity. Weight-based dosing alone does not make formulations or drug exposures equivalent. 1 6
Follow renal function, blood pressure and interactions; tremor and gingival enlargement are original teaching points, particularly for ciclosporin. Tacrolimus has less uveitis evidence in the original account. The historical 50% and 60–70% figures below do not establish lower or higher efficacy than antimetabolites. Reproductive compatibility is a conditional specialist assessment. 1 11
| Drug | Administration | Original response claim | Risks and interpretation |
|---|---|---|---|
| Ciclosporin | Daily, weight- and formulation-dependent. | Slow onset; ~50%; originally called less effective than antimetabolites. | No cross-cohort efficacy ranking. Renal toxicity, hypertension, tremor, gingival enlargement; check creatinine, blood pressure and interactions. Conditional pregnancy/lactation compatibility. |
| Tacrolimus | Daily, weight- and formulation-dependent; original lower-dose potency comparison. | Original 60–70%, less studied in uveitis. | Dose size does not prove superior clinical benefit. Renal toxicity and blood-pressure/interaction monitoring; conditional reproductive compatibility. |
06Reserve alkylating agents for carefully selected severe disease
Cyclophosphamide and chlorambucil are cytotoxic alkylating agents. Their possible role in severe refractory sight-threatening disease must be weighed against marrow suppression, infection, infertility and malignancy, with reproductive counselling. The original response, timing and white-cell targets below are historical assertions, not a ready-to-use treatment protocol. 1 12
The inspected UK chlorambucil product is an oral 2 mg tablet for specified malignancies, under experienced supervision. It does not verify the original intravenous route or a uveitis indication, nor prove that no other formulation exists anywhere. A claim of better tolerability than cyclophosphamide is not established here; cumulative exposure, including the original >12-month concern, needs disease- and product-specific appraisal. 12
| Drug | Original regimen claim | Original response/onset claim | Limits and safety |
|---|---|---|---|
| Cyclophosphamide | Oral or IV; original white cells 3,000–4,000/µl and 6–12 months. | 2–8 weeks; ~76%, adverse effects ~33%. | Historical unverified protocol/denominators. Infertility, marrow suppression, infection, malignancy and reproductive risks require specialist control; no target-based self-titration. |
| Chlorambucil | Original oral or IV with same white-cell target; inspected UK 2 mg product is oral. | Original slower but better tolerated; cancer concern particularly >12 months. | Comparative tolerability and IV route not verified. Marrow, fertility and malignancy risks; local indication/formulation and protocol need confirmation. |
07Use TNF inhibitors with indication-specific evidence
Tumour necrosis factor alpha (TNF-α) inhibitors include adalimumab and infliximab. Adalimumab is a recombinant human monoclonal antibody; the original “fully humanised” description is corrected. Authorisation depends on country, age and anatomical form: the EMA adult indication covers specified noninfectious intermediate, posterior and panuveitis situations; the paediatric chronic noninfectious anterior indication starts at 2 years under stated conditions. 2
The adult EMA uveitis regimen is an 80 mg loading dose followed by 40 mg every other week, starting one week later. This is label context, not an individual prescription. The original onset of 2–6 weeks and 65–80% response are not universal trial-derived expectations; verify response and harms in the patient’s disease. 2 4 5
VISUAL I was a double-masked placebo-controlled trial in active adult intermediate, posterior or panuveitis with a mandated 15-week steroid taper. In 217 intention-to-treat patients, median time to composite treatment failure was 24 versus 13 weeks; hazard ratio 0.50 (95% CI 0.36–0.70). Adverse and serious adverse event rates were 1052.4 versus 971.7 and 28.8 versus 13.6 per 100 person-years. The composite is not a cure rate, and follow-up under a trial taper differs from every clinical setting. 4
VISUAL II studied inactive disease controlled with prednisone 10–35 mg/day and taper from week 2. Of 226 intention-to-treat patients, failure occurred in 45/115 (39%) on adalimumab versus 61/111 (55%) on placebo; hazard ratio 0.57 (95% CI 0.39–0.84). Median time to failure was not estimated beyond 18 months versus 8.3 months. Unequal median follow-up, 245 versus 155 days, prevents reading these proportions as equal-time absolute risks. Both VISUAL trials were AbbVie-funded; complete reports and protocols remain needed for fuller appraisal. 5
Screen for relevant infection, including tuberculosis (TB) using appropriate history and testing such as PPD or IGRA, and assess hepatitis B as required. Humira SmPC 4.3 lists active TB and other severe infections; latent TB is addressed through prophylaxis before treatment and specialist risk assessment in 4.4. Demyelinating disease is a separate warning: intermediate uveitis requires neurological evaluation before and during therapy, but that wording does not mandate brain MRI in every patient. Established multiple sclerosis (MS) changes treatment selection. 2
| Drug | Structure / indication | Regimen context | Safety and evidence boundary |
|---|---|---|---|
| Adalimumab (Humira) | Human monoclonal antibody; specific EMA adult and paediatric indications, not a global “only approved” claim. | Adult 80 mg, then 40 mg every other week from week 1; original onset 2–6 weeks, response 65–80% not universal. | Active TB/severe infection contraindications; latent TB preventive management; demyelination warning and neurological evaluation. VISUAL results are composite time-to-failure outcomes. |
| Infliximab | Chimeric antibody; original 75% human / 25% mouse description retained as a teaching approximation; uveitis use may be off label. | Original 5–10 mg/kg IV at weeks 0, 2, then every 4–8 weeks is incomplete as a verified induction protocol. | Check actual indication and induction schedule rather than prescribing from this row. Infusion/allergic reactions, infection/TB and neurological risks; not proven identical benefit or contraindication wording to adalimumab. |
08Keep other immune treatments diagnosis-specific
Rituximab targets CD20-positive B cells. The original ocular cicatricial pemphigoid, orbital inflammation, scleritis and systemic vasculitis examples remain distinct diseases, not interchangeable uveitis indications. An infusion regimen cannot be derived from a single blood CD20 count; indication, immune status, infection risk and specialist protocols matter. 6
Interferon is retained as a disease-specific immunomodulatory option, particularly in Behçet disease. The original “up to 90%” response and mandatory use only after TNF failure lack a verified comparable population and endpoint here. Flu-like symptoms, worsening depression and suicidal thoughts are important safety concerns, not a reason to assume all patients will experience them. 6 14
Intravenous immunoglobulin (IVIG) is donor-derived and is discussed in rare selected situations where other immune suppression is problematic, including recurrent severe infection. This does not establish a standard uveitis indication or freedom from harm. Cost, supply, formulation and patient-specific risk require specialist review. 6
| Treatment | Mechanism | Original clinical settings | Limits and safety |
|---|---|---|---|
| Rituximab | Anti-CD20, B-cell depletion. | Ocular cicatricial pemphigoid, orbital inflammation, scleritis, systemic vasculitis. | Different indications; not obligatory second line for all uveitis. IV specialist regimen, not dose by CD20 alone; immune/infection/infusion monitoring. |
| Interferon | Immunomodulation. | Behçet; original up to 90% response / after TNF failure. | Original percentage and fixed sequence unverified; flu-like symptoms, depression and suicidal thoughts require assessment. |
| IVIG | Donor immunoglobulins, IV. | Rare selected use when other IMT is problematic, including recurrent severe infection. | Not a routine proven uveitis algorithm or harm-free alternative; supply, cost and specialist assessment matter. |
09Use the cases to test the treatment decision
These are educational cases from the original page, not identifiable patient records or validated comparative treatment experiments. They test how systemic disease changes a decision; their table retains all original ages and the 11-month relapse interval. 2 9 14
Steroid response in the post-transplant case does not prove noninfectious disease or exclude a lymphoma-related masquerade. Similarly, recurrent Behçet inflammation on adalimumab does not by itself prove anti-drug antibodies or establish that adding MTX is better than switching or adjusting treatment. Any additional immune suppression requires a renewed safety assessment. 2 6 9 14
| Case | Findings | Decision to examine | Reasoned interpretation |
|---|---|---|---|
| 1 | 18-year-old woman, intermediate uveitis with vitritis/vasculitis and transient neurological symptoms; MRI confirms MS. | Which treatment poses a demyelination concern? | Avoid treating TNF inhibition as the default; coordinate a suitable alternative with neurology. Preserve the distinction between a clinical avoidance decision and the formal Humira 4.3 contraindication list. |
| 2 | 30-year-old woman after bone-marrow transplantation for lymphoma, severe apparently noninfectious uveitis responding to systemic steroids that must be reduced. | What to do at relapse? | Reassess infection and masquerade with transplant/oncology colleagues. Ozurdex may be a local option after product-specific checks; it is not proven the sole best treatment, and all systemic treatment is not automatically contraindicated. |
| 3 | 45-year-old man with Behçet disease and severe posterior uveitis with occlusive vasculitis. | Which early treatment strategy? | Urgent specialist inflammation control and an effective steroid-sparing plan. Current EULAR guidance supports early monoclonal TNF inhibition in organ-threatening disease; adalimumab is not the only possible first-line answer. |
| 3, continuation | Relapse after 11 months of adalimumab. | Add MTX, adjust or switch? | Confirm activity, diagnosis, adherence and exposure; consider anti-drug antibodies where useful. Combination may be considered, but this illustration proves neither immunogenicity nor superiority over switching or dose adjustment. |
10Monitor response and plan a cautious long-term taper
Recheck the diagnosis when treatment fails, including targeted TB and syphilis assessment and masquerade evaluation when indicated. Track visual function as well as anterior cells, vitreous activity, retinal or choroidal lesions and macular oedema; anatomical improvement alone is not proof of durable visual benefit. Decisions about combination therapy or an early biologic depend on the disease and safety profile. 1 6
Use a written, drug-specific monitoring plan. The original steroid schedule—blood pressure, weight and glucose every 3 months, yearly lipids, bone density after 3 months then yearly—and calcium/vitamin D advice remain historical teaching points. Current bone protection and testing depend on fracture risk, exposure and multidisciplinary guidance; these intervals and supplements are not a complete universal prevention plan. 1
The original antimetabolite blood-count/liver interval of 6 weeks and initial weekly alkylator counts likewise do not replace current labels. For example, the inspected Nordimet label specifies more frequent early tests and risk-dependent later intervals; the CellCept monitoring schedule is from transplantation. Check renal function, interactions, infection, pregnancy planning and the reason for any abnormal test rather than applying one class-wide timetable. 7 8 12
The original approach continues IMT after steroid withdrawal and considers taper after at least 2 quiet years, with visits every 3 months. DOG/BVA 24a 2020 describes a ≥24-month quiet interval before DMARD reduction at evidence level III in its intermediate-uveitis context. This is a cautious framework, not a universal remission guarantee, a current disease-specific rule for all forms, or permission to stop surveillance. 1
| Class | Examples | Role | Major safety concerns | Monitoring focus |
|---|---|---|---|---|
| Corticosteroids | Prednisone, dexamethasone, prednisolone acetate | Rapid control by the appropriate route. | Cataract/IOP; systemic metabolic, cardiovascular, bone and psychiatric harm. | IOP/lens; BP, glucose and bone risk; individual schedule. |
| NSAIDs | Ketorolac, ibuprofen | Selected CME/anterior adjunct; distinct scleritis context. | Ocular-surface/corneal risk; GI bleeding, renal/CV harm. | Systemic blood count, liver/renal tests and BP as indicated. |
| Antimetabolites | MTX, AZA, MMF | Sustained steroid-sparing therapy. | Marrow/liver toxicity, nausea; MTX/MMF reproductive hazards. | Blood count, liver/renal assessment; original 6-week interval is not universal. |
| Calcineurin inhibitors | Ciclosporin, tacrolimus | Selected alternatives or combination. | Renal toxicity, hypertension, interactions. | Creatinine, BP and drug-specific laboratory/exposure checks. |
| Alkylators | Cyclophosphamide, chlorambucil | Selected severe refractory disease. | Marrow suppression, infection, infertility, malignancy. | Close blood counts, urinalysis where relevant; original initial weekly interval requires protocol. |
| TNF inhibitors | Adalimumab, infliximab | Specified severe/refractory disease and Behçet contexts. | Infection/TB, demyelination, infusion/injection reactions. | TB/infection screening, blood count/liver checks as appropriate; neurological assessment. |
| Other immune treatments | Rituximab, interferon; selected IVIG | Diagnosis-specific refractory situations. | Infusion reactions; depression/suicidality with interferon; immune complications. | Blood count and specialist immune monitoring; CD20 alone is insufficient; mental-health assessment. |
What are the main learning points of this lecture?
Establish the cause and site, identify sight- or organ-threatening disease, control inflammation promptly and choose a sustainable steroid-sparing plan with appropriate monitoring. The ladder is diagnosis-led; the individual findings determine whether local, conventional systemic or early biological treatment is suitable.
Which findings require urgent assessment?
Rapid visual deterioration, severe pain, marked inflammation, raised eye pressure or suspected infection or neurological disease need prompt assessment. Sudden visual-field loss and symptoms after an injection also require urgent review; a treatment response does not exclude an infectious or masquerade cause.
References and access status
- 1DOG/BVA 24a · Uveitis intermedia · 14.06.2020
Selected PDF pages 1–2, 8–11 and 18–20 read. Historical 2020 guidance; not the whole document, algorithm image, methods or references.
- 2EMA · Humira · product information
Selected actual EMA SmPC sections 2, 4.1, adult uveitis 4.2, 4.3 and infection/TB/HBV/neurological parts of 4.4 read. Not all formulations, complete SmPC, study images or leaflet; German local details remain pending.
- 3FAST · JAMA 2019 · PMID 31503307
Complete indexed abstract and selected publisher main text: methods, six-month results including secondary noninferiority, limitations and funding read. Not complete report/images/protocol/SAP/supplements. Secondary comparisons exploratory; missing data and phenotype applicability matter.
- 4VISUAL I · 2016 · PMID 27602665
Complete indexed abstract read. Active-disease placebo RCT; full report/protocol/supplements and image tables unread. AbbVie funded.
- 5VISUAL II · 2016 · PMID 27542302
Complete indexed abstract read. Inactive-disease placebo RCT; full report/protocol/supplements unread. Unequal follow-up and unresolved adverse-event denominator questions; no erratum inferred. AbbVie funded.
- 6FOCUS · 2018 · PMID 29310963
Complete indexed abstract read: systematic review plus Delphi consensus, not a drug-comparison RCT. Full publisher PDF returned HTML; full statements, evidence tables and appendices unread.
- 7EMA · Nordimet · product information
Selected actual SmPC indications/dosing, contraindications, early safety/monitoring text read. This product lists other inflammatory indications, not uveitis; complete label/leaflet and all formulations unread.
- 8EMA · CellCept · product information
Selected actual SmPC pregnancy/breastfeeding, infection and blood-count monitoring text read. Transplant label context; not complete label or a uveitis-specific regimen.
- 9EMA · Ozurdex · product information
Selected actual SmPC indications, dosing, contraindications and early ocular safety text read. Not complete label/trial images/leaflet; duration is not guaranteed control.
- 10Difluprednate trial · 2014 · PMID 24677110
Complete indexed abstract read: short anterior-uveitis randomised trial. Main paper/protocol/noninferiority-margin methods unread; attempted full-text endpoints returned challenge/JSON error, not article access.
- 11EULAR · reproduction · 2024 update / 2025 · PMID 40287311
Complete indexed abstract read. Updated reproductive consensus informed by systematic review; complete recommendations/evidence tables/supplements unread. Specialist context, not automatic local-label permission.
- 12Chlorambucil 2 mg · UK SmPC · 03.11.2015
Selected UK SmPC 4.1–4.4 through marrow monitoring read; last site update 2015, not a 2026 clinical revision. Oral cancer product; complete label and local German formulation/uveitis protocol unread.
- 13Iluvien · UK SmPC · 24.02.2025
Selected UK SmPC 4.1–4.4 and pregnancy/lactation text read; 24 February 2025 version. Not complete studies or German authorisation verification; release duration differs from guaranteed control.
- 14EULAR · Behçet · 2025 update / 2026 · PMID 41876291
Complete actual NCBI abstract read: 29-member task force, systematic review/Delphi, 5 principles/12 recommendations. Main publisher access failed; indexed ocular recommendations located, not full text appraised. No claim of full guideline/underlying evidence access.
Original lecture links
For patients
Uveitis means inflammation inside the eye. Treatment depends on its cause and location; an infection or a condition imitating inflammation may need a different treatment.
Steroids may control inflammation quickly, while another medicine may help reduce long-term steroid exposure. Drops, injections and tablets treat different situations; do not change the dose or stop systemic steroids without your treating team.
Keep eye and blood-test appointments and discuss pregnancy plans, infections and new symptoms with the team. A medicine described as compatible with pregnancy still needs an individual plan.
Seek urgent assessment for sudden or worsening vision loss, a new visual-field defect or severe eye pain, especially after an injection. Contact the team promptly for suspected infection, pressure-related symptoms or new neurological symptoms; severe illness needs emergency care.